Truist Securities Maintains Buy on Agilon Health, Lowers Price Target to $27
Portfolio Pulse from richadhand@benzinga.com
Truist Securities analyst Jailendra Singh maintains a Buy rating on Agilon Health (NYSE:AGL) but lowers the price target from $35 to $27.
June 20, 2023 | 1:30 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Truist Securities maintains a Buy rating on Agilon Health (NYSE:AGL) but lowers the price target from $35 to $27.
The news directly mentions Agilon Health (NYSE:AGL) and its lowered price target by Truist Securities. While the Buy rating is maintained, the lowered price target may cause mixed reactions among investors, leading to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100